跳至主要内容
临床试验/NCT06484478
NCT06484478已完成不适用

A Real-world Monitoring Project Exploring Day-to-day Physical Activity, Sleep, and Quality of Life in Individuals With Fabry Disease.

Royal Free Hospital NHS Foundation Trust1 个研究点 分布在 1 个国家目标入组 100 人开始时间: 2024年11月5日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
100
试验地点
1
主要终点
Quality of life - via EuroQol five-dimension questionnaire (EQ-5D-5L).

研究概览

简要总结

Despite improvements in Fabry disease care in recent years, many patients still have poor outcomes. In addition to the many physical symptoms that patients can experience, the disease also places individuals at an increased risk of mental health conditions, such as anxiety and depression. Low physical activity levels and increased sedentary time are detrimentally associated with anxiety, depression and quality of life in the general population. Currently, no such research has been conducted in individuals with Fabry disease.

Data will consist of: (1) information from hospital medical records, (2) patient reported outcomes collected via questionnaires, and (3) measurements from a clinical-grade wearable device.

Individuals with Fabry disease aged 18 years or above will be considered for eligibility screening.

详细描述

Trial assessments:

Baseline questionnaires

Baseline questionnaires will include the Hospital Anxiety and Depression Scale (HADS) and the EuroQol 5-dimension questionnaire (EQ-5D-5L). This will be administered via Qualtrics.

Thigh-worn device (activPAL)

Participants will attach the activPAL device to their anterior thigh for 8 days and continue their usual daily behaviour throughout the week. This will measure sitting, standing, stepping and sleep time. This device is accompanied by a hard copy daily diary, where participants will be asked to input the time they wake up, they get out of bed, they get into bed, and when they go to sleep.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Cross Sectional

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者
否

入选标准

  • •Diagnosis of Fabry disease documented by genotyping and/or enzymatic analysis.
  • •Resident in the UK.
  • •Aged 18 years and over.
  • •Capable of providing informed consent.
  • •Physically able to stand and ambulate independently.

排除标准

  • •A known allergy to any materials in the wearable device.
  • •Not able to have or use a wearable.
  • •Taking part in an interventional study which would preclude real-world data collection.
  • •Unable to communicate in English to a sufficient level to permit engagement in the study.

研究组 & 干预措施

Adults with Fabry disease

干预措施: Wearable technology monitoring (Other)

结局指标

主要结局

Quality of life - via EuroQol five-dimension questionnaire (EQ-5D-5L).

时间窗: Baseline

Quality of life measured using the self-report EuroQol five-dimension questionnaire (EQ-5D-5L). The questionnaire is comprised of five dimensions which are each divided into five levels of severity i.e. 1 = no problem, 2 = slight problems, 3 = moderate problems, 4 = severe problems, and 5 = unable to/extreme problems. A five-digit health state score is then found by combining the levels of severity for each dimension i.e. 11111 is the best health state and 55555 is the worst health state.

次要结局

  • Anxiety(Baseline)
  • Depression(Baseline)

研究者

发起方
Royal Free Hospital NHS Foundation Trust
申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验